Unicycive Therapeutics reported cash from operations of -$7.60M and free cash flow of -$7.60M for the quarter ended Jun 2026, up 9.7% year over year. This cash flow statement covers 25 quarters of results from Jun 2020 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Cash Flow Statement | Jun2020 | Sep2020 | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||||||||||||||||
| Net Income | -4.77M | -2.75M | -3.54M | -3.64M | -5.56M | -5.33M | -4.20M | -4.12M | -5.73M | -6.19M | -9.15M | -6.96M | -5.85M | -8.97M | -7.78M | -6.82M | -7.08M | -6.90M | -8.04M | -9.70M | |||||
| Share-based Compensation | 0.24M | 0.29M | 0.29M | 0.27M | 0.20M | 0.14M | 160.96M | 160.96M | 0.55M | 10.32M | 13.09M | 13.67M | 0.58M | 13.78M | 1.42M | 2.03M | 0.78M | 2.19M | 2.88M | ||||||
| Gains from Investment Securities | 10.40M | -0.30M | -1.40M | -0.07M | 11.81M | -16.81M | -1.75M | 12.60M | -8.35M | -0.37M | -1.07M | 7.78M | 4.80M | -7.98M | |||||||||||
| Cash from Operations | -3.47M | -1.40M | -2.96M | -3.05M | -3.56M | -6.08M | -3.92M | -5.50M | -4.42M | -4.44M | -6.46M | -6.32M | -9.25M | -6.55M | -8.90M | -8.42M | -5.96M | -8.03M | -6.24M | -7.60M | |||||
| Depreciation, Depletion & Amortization | |||||||||||||||||||||||||
| Amortizatization of Intangibles | 0.04M | 0.04M | 0.04M | 0.04M | 0.04M | 0.04M | 0.08M | 0.08M | 0.08M | 0.28M | -0.11M | 0.12M | 0.13M | 0.13M | 0.13M | 0.14M | 0.14M | 0.20M | 0.14M | ||||||
| Change in Working Capital | |||||||||||||||||||||||||
| Change in Accured Expenses | 0.44M | 0.78M | 0.02M | -0.07M | 1.95M | -0.64M | -0.19M | -0.44M | 1.48M | 0.43M | 0.82M | -0.37M | -0.63M | 0.97M | 0.79M | -2.26M | 0.78M | -1.81M | 2.29M | 0.18M | |||||
| Other Working Capital Changes | 0.09M | -0.26M | -0.04M | -0.04M | -0.32M | 0.25M | -0.34M | 1.11M | 1.11M | -0.77M | -1.34M | -0.36M | 3.39M | -0.86M | 2.48M | -0.09M | 0.39M | 0.10M | 1.27M | 0.94M | |||||
| Investing Activities | |||||||||||||||||||||||||
| Capital Expenditures | 0.00M | 0.01M | 0.02M | 0.02M | 0.02M | 0.02M | 0.01M | 0.00M | 0.01M | -0.00M | |||||||||||||||
| Cash from Investing Activities | -0.00M | -0.01M | -0.02M | -0.02M | -0.02M | -0.02M | -0.01M | -0.00M | -12.07M | -5.16M | -0.02M | ||||||||||||||
| Financing Activities | |||||||||||||||||||||||||
| Other financing activities | 22.15M | -3.81M | 0.16M | 1.34M | |||||||||||||||||||||
| Debt Issuance and Repayment | |||||||||||||||||||||||||
| Long-Term Debt Issuances | |||||||||||||||||||||||||
| Short-Term Debt issuances | 0.90M | ||||||||||||||||||||||||
| Change in Capital Stock | |||||||||||||||||||||||||
| Net Shares Issued and Repurchased | 8.99M | 0.02M | 3.37M | 0.11M | 0.67M | ||||||||||||||||||||
| Net Equity Issued and Repurchased | -3.81M | ||||||||||||||||||||||||
| Misc. | |||||||||||||||||||||||||
| Cash from Financing Activities | 21.48M | 27.80M | -0.05M | -0.20M | 45.69M | -0.81M | -0.16M | 0.36M | 2.55M | 10.98M | 26.33M | 6.61M | 19.57M | 14.44M | |||||||||||
| Change in Cash | 18.01M | -1.43M | -2.96M | -3.05M | -3.56M | -6.55M | 23.88M | -5.51M | -4.47M | -4.64M | 39.23M | -7.15M | -9.43M | -6.21M | -6.37M | 2.56M | 20.37M | -13.50M | 8.17M | 6.81M | |||||
| Free Cash Flow | -3.47M | -1.40M | -2.96M | -3.05M | -3.56M | -6.08M | -3.92M | -5.50M | -4.42M | -4.44M | -6.46M | -6.34M | -9.28M | -6.57M | -8.92M | -8.43M | -5.96M | -8.03M | -6.25M | -7.60M | |||||
| Net Cash Flow | 18.01M | -1.40M | -2.96M | -3.05M | -3.56M | -6.08M | 23.88M | -5.50M | -4.47M | -4.64M | 39.23M | -7.15M | -9.43M | -6.21M | -6.37M | 2.56M | 20.37M | -13.50M | 8.17M | 6.81M |